Join Our Newsletter

U.S. Stem Cell, Inc. - USRM

RSI %R Tweets Wolf Odds
50 -82 13 8.97%

Industry: Biotechnology / Sector: Healthcare

USRM Chart

USRM Quote

Prev Close: 0.036
Open: 0.0398
Last Trade: 0.035
Change %: -2.780%
Change: -0.0010000
Volume: 965901
Avg Vol: 2095154
Relative Vol: 0.46
Day Range: 0.033 -0.0398
52-Week Range: 0.002 - 0.179
Market Cap: 9.08M
Float: 289.83M
Shares Outstanding: 336.46M
Insider Owned: 4.02%
Institution Owned: 0.00%
Beta: 12.18
PE Ratio: 0.00
EPS: -0.015

USRM Detailed Stats

RSI:49.72 %K:18.29 Wolf Odds: 8.97% Tweets Today:13 SMA14:0.0411
stochRSI:0.00 %D:24.76 Wolf Trend:0.31 Tweet Avg:16 Pivot Price:0.0359333
%R:-81.71 %B:0.19 Wolf 3-Day:0.29 Avg. Change 3-Day:+1.487% Resistance 1:0.0388667
MFI:52.38 Bandwidth:0.474494 Wolf 7-Day:0.31 Avg. Change 7-Day:-2.401% Resistance 2:0.0427333
WolfPeak:0.01 Vortex Indicator:0.02 Wolf 14-Day:0.42 Avg. Change 14-Day:-0.48% Support 1:0.0320667
ROC 7/14:-16.6667/-28.2787 Aroon Oscillator:-71.4286 EOM:-0.000230 Relative Vol:0.46 Support 2:0.0291333
RSI Alert:None WolfPeak Alert:None Vortex Alert:Potential Bear Aroon Alert:None EOM Alert:None

Featured News *

USRM News

USRM Description

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient?s heart with autologous muscle cells or cells from a patient?s body for improving cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, lower limb ischemia, and rheumatoid arthritis. The company?s product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It also offers MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training services, cell collection, and cell storage services; and sells cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.
Website: http://www.us-stemcell.com

USRM Comments

Recent USRM Tweets

Powered by Ekonomys ver. 9

StockWolf is dedicated to Penny Stock quotes and data to provide information, news, and education on penny stocks to help in your due diligence.

30min+ delay on data. All data is picked with automated algorithms and not vetted for accuracy. Please, read ALL information and disclaimers before using our service. StockWolf is not a licensed financial adviser, and not liable for your loses. Trade responsibly. This site is for education purposes only not a recommendation to buy/sell